TITLE

Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT)

AUTHOR(S)
C. Lange; N. Feltgen; B. Junker; K. Schulze-Bonsel
PUB. DATE
January 2009
SOURCE
Graefe's Archive of Clinical & Experimental Ophthalmology;Jan2009, Vol. 247 Issue 1, p137
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract Purpose  The Freiburg Visual Acuity Test (FrACT) has been suggested as a promising test for quantifying the visual acuity (VA) of patients with very low vision, a condition often classified using the semi-quantitative clinical scale “counting fingers” (CF), “hand motion” (HM), “light perception” (LP) and “no light perception”. The present study was designed to assess FrACT performance in a sizable number of CF, HM, and LP patients in order to generate a setting for future clinical studies in the low vision range. Methods  We examined a total of 41 patients (LP, n = 11; CF, n = 15; HM, n = 15) with various eye diseases (e.g., diabetic retinopathy, ARMD), covering the clinical VA scale from LP to CF. The FrACT optotypes were presented at a distance of 50 cm on a 17-inch LCD monitor with four random orientations. After training, two FrACT measurements (test and retest) were taken, each comprising 30 trials. Results  FrACT measures reproducibly the VA of CF and HM patients. In CF patients, FrACT resulted in a mean logMAR = 1.98 ± 0.24 (corresponding to a decimal VA of 0.010), for HM in a mean logMAR = 2.28 ± 0.15 (corresponding to a decimal VA of 0.0052). In all LP patients the FrACT values were close to what would be obtained by random guessing. The mean test–retest 95% confidence interval was 0.21 logMAR for CF patients and 0.31 logMAR for HM respectively. Test-retest variability declined from 24 to 30 trials, showing that at least 30 trials are necessary. Conclusion  FrACT can reproducibly quantify VA in the CF and HM range. We observed a floor effect for LP, and it was not quantifiable further. Quantitative VA measures are thus obtainable in the very low-vision range using FrACT.
ACCESSION #
35362726

 

Related Articles

  • Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4). Sivaprasad, Sobha; Crosby-Nwaobi, Roxanne; Esposti, Simona; Peto, Tunde; Rajendram, Ranjan; Michaelides, Michel; Hykin, Philip // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: To describe structural and functional changes associated with diabetic macular oedema (DMO) treated with intravitreal bevacizumab over 24 months. Methods: A post-hoc analysis of the data of 34 patients that completed 24 months follow-up in the intravitreal bevacizumab arm of a...

  • Diabetic Eye Disease. Pelino, Carlo J.; Pizzimenti, Joseph J. // Review of Optometry;11/15/2014 Supplement Annual Guide to Retinal Disease, p7 

    The article discusses eye disease diabetic retinopathy (DR) and reviews research and clinical trials in the disease treatment. Research reviewed includes Early Treatment Diabetic Retinopathy Study (ETDRS), Diabetic Retinopathy Study (DRS) and Diabetic Retinopathy Vitrectomy Study (DRVS). Other...

  • Influence of Uncomplicated Phacoemulsification on Central Macular Thickness in Diabetic Patients: A Meta-Analysis. Liu, Jianping; Jones, Richard Edward; Zhao, Jiangyue; Zhang, Jinsong; Zhang, Fan // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Objective: To evaluate the effect of uncomplicated phacoemulsification on central macular thickness (CMT) and best corrected visual acuity (BCVA) in both diabetic patients without diabetic retinopathy (DR) and diabetic patients with mild to moderate non-proliferative diabetic retinopathy...

  • Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Claessen, Heiner; Genz, Jutta; Bertram, Bernd; Trautner, Christoph; Giani, Guido; Zöllner, Iris; Icks, Andrea // European Journal of Epidemiology;Jul2012, Vol. 27 Issue 7, p519 

    The objectives of this study are to estimate the recent population-based incidences of all-cause and cause-specific blindness in Germany and compare them with results from a similar study conducted in 1994-1998. All blindness allowance recipients newly registered between January 2008 and...

  • A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Nicholson, Benjamin P.; Schachat, Andrew P. // Graefe's Archive of Clinical & Experimental Ophthalmology;Jul2010, Vol. 248 Issue 7, p915 

    Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population worldwide. Many observational and preclinical studies have implicated vascular endothelial growth factor (VEGF) in the pathogenesis of DR, and recent successes with anti-VEGF therapy for age-related macular...

  • New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Bandello, F; Cunha-Vaz, J; Chong, N V; Lang, G E; Massin, P; Mitchell, P; Porta, M; Prünte, C; Schlingemann, R; Schmidt-Erfurth, U // Eye;Apr2012, Vol. 26 Issue 4, p485 

    The current standard therapy for patients with diabetic macular oedema (DME)-focal/grid laser photocoagulation-usually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment...

  • Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial. Preti, Rony Carlos; Vasquez Ramirez, Lisa Mariel; Ribeiro Monteiro, Mario Luiz; Carra, Mario Kehdi; Pelayes, David E.; Takahashi, Walter Yukihiko // British Journal of Ophthalmology;Jul2013, Vol. 97 Issue 7, p885 

    Purpose To compare the effect on contrast sensitivity (CS) measurements of panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections versus PRP alone in high risk proliferative diabetic retinopathy (HR-PDR). Design Prospective, randomised, masked, controlled...

  • Subconjunctival sirolimus in the treatment of diabetic macular edema. Krishnadev, Nupura; Forooghian, Farzin; Cukras, Catherine; Wong, Wai; Saligan, Leorey; Chew, Emily; Nussenblatt, Robert; Ferris, Frederick; Meyerle, Catherine // Graefe's Archive of Clinical & Experimental Ophthalmology;Nov2011, Vol. 249 Issue 11, p1627 

    Background: Diabetic macular edema (DME) is a leading cause of blindness in the developed world. Sirolimus has been shown to inhibit the production, signaling, and activity of many growth factors relevant to the development of diabetic retinopathy. This phase I/II study assesses the safety of...

  • A new Gujarati language logMAR visual acuity chart: Development and validation. Sailoganathan, Ananth; Siderov, John; Osuobeni, Ebi // Indian Journal of Ophthalmology;Oct2013, Vol. 61 Issue 10, p557 

    Aims: Gujarati is the main spoken language of a large proportion of the population of India. The aim of this study was to develop and validate a new Minimum Angle of Resolution (logMAR) visual acuity chart in the Gujarati language. Materials and Methods: A new Gujarati visual acuity chart was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics